Wednesday, February 10, 2010, 9:06am EST - Canadian Markets open in 24 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Acadia Pharmaceuticals Inc. (ACAD)

 On Feb 9: 1.30 USD   0.00 (0.00%)  
MORE ON ACAD
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
ACADIA Pharmaceuticals Inc. (NGM:ACAD) Delayed quote dataEdit
Last Trade: 1.30 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 1.30
Open: N/A
Bid: 1.23 x 11000
Ask: 1.31 x 400
1y Target Est: 20.11
Day's Range: N/A - N/A
52wk Range: 0.75 - 6.60
Volume: 0
Avg Vol (3m): 591,383
Market Cap: 49.75M
P/E (ttm): N/A
EPS (ttm): -1.55
Div & Yield: N/A (N/A%)
Acadia Pharmaceuticals Inc. (ACAD)
1d  5d  3m  6m  1y  2y  5y  max 
 Add ACAD to Portfolio   Download Data

HEADLINES
• ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 8, 2010
Business Wire (Mon, Feb 1)
• ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online (Thu, Jan 28)
• ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Finan
EDGAR Online (Thu, Dec 17)
• ACADIA PHARMACEUTICALS INC Financials
EDGAR Online Financials (Sat, Nov 14)
• RHI Entertainment, Opnext: Midday Volume Plays
at TheStreet.com (Tue, Nov 10)
• ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
EDGAR Online (Mon, Nov 9)
• ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors
EDGAR Online (Thu, Oct 15)
• ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online (Tue, Oct 6)
• Mannkind Falls on Talk of Partner, FDA Delay: BioBuzz
at TheStreet.com (Tue, Oct 6)
• No Lupus Confab Invite for Immunomedics: BioBuzz
at TheStreet.com (Tue, Oct 6)
More Headlines for ACAD...
ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : N/A
Avg Rec (current)*: 1.9
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Acadia Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices